Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

Reuters is tracking how companies are responding to the threat posed by <a href=" target="_blank" rel="noopener noreferrer ...

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.